NCT02990481View on ClinicalTrials.gov

A Phase 1 Study Evaluating the Safety of TRK-950 in Patients With Advanced Solid Tumors

PHASE1CompletedINTERVENTIONAL
Enrollment

38

Participants

Timeline

Start Date

March 6, 2017

Primary Completion Date

September 16, 2019

Study Completion Date

September 16, 2019

Conditions
Locally Advanced or Metastatic Solid CarcinomasColon CancerCholangiocarcinoma
Interventions
BIOLOGICAL

TRK-950

Intravenously over 60 minutes, on day 1, 8 and 15 of each cycle

BIOLOGICAL

TRK-950

"Low dose: intravenously over 60 minutes, on day 1, 8, 15 and 22 of each cycle~High dose: intravenously over 60 minutes, on day 1 and 15 of each cycle"

BIOLOGICAL

TRK-950

Low dose: Intravenously over 60 minutes, on day 1, 8, 15 and 22 of each cycle

Trial Locations (3)

69373

Centre Léon Bérard, Lyon

85054

Mayo Clinic, Phoenix

85258

HonorHealth Research Institute, Scottsdale

All Listed Sponsors
lead

Toray Industries, Inc

INDUSTRY

NCT02990481 - A Phase 1 Study Evaluating the Safety of TRK-950 in Patients With Advanced Solid Tumors | Biotech Hunter | Biotech Hunter